Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary Elizabeth M. Percival, Anjali S. Advani, James M. Foran, Steven M. Horwitz, Matthew G. Mei, Jasmine Zain, Kerry J. Savage, Christiane Querfeld, Oleg E. Akilov, Lisa D.S. Johnson, Tina Catalano, Penka S. PetrovaRobert A. Uger, Eric L. Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A. O'Connor

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences